GERON CORP
GERNNASDAQTrading Snapshot
- Day Range
- $256.15 – $261.94
- 52-Week Range
- $1.04 – $2.01
- Volume
- $2.22B
- Avg Volume
- $1.54B
- Shares Outstanding
- 641.5M
- Next Earnings
- Dec 2, 2026
Fundamentals Snapshot
- Annual Revenue
- $184M
- Last Q Revenue
- $57M
- P/E Ratio
- -12.4
- P/S Ratio
- 3.9x
- EPS (TTM)
- $-0.10
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +3.3%
Why Investors Own GERN
- ✓High-growth profile — revenue up +10.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 68% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
GERON CORP
GERN
StockOtter · stockotter.spaceAbout GERON CORP
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?PR NewswireNEW YORK, Sept. 25, 2026Shareholders are encouraged to contact the firm
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN
Geron Investigation Initiated: Kahn Swick and Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERNPR NewswireNEW YORK and NEW ORLEANS, Se
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today reporte
Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expands
Geron NASDAQ: GERN executives said the company remains on track to generate 2026 RYTELO net revenue of $220 million to $240 million, with Chief Executive Officer Harout Semerjian saying the company now expects results to
Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands
Geron NASDAQ: GERN said it expects full-year net revenue from RYTELO to land in the mid-to-high end of its previously stated range, or approximately $230 million to $240 million, as the company continues to expand use of
Kuehn Law Encourages Investors of Geron Corporation to Contact Law Firm
NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Geron Corporation (NASDAQ: GERN) breached their fiduciary duties to s